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Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of the coronavirus disease 19 (COVID-19) pandemic has claimed the lives of
roughly 6.2 million people worldwide as of May 2022. The virus’s main protease (Mpro ) has
been identified as an attractive drug target due to the critical role it plays in the viral life cycle.
The roughly 34 kDa Mpro cleaves functional viral polypeptides out of two long polyproteins at
conserved cut sites, allowing them to fulfill their role in processes like transcription and
replication. Here, we have studied the enzymatic activity and inhibition of Mpro and tested known
(carmofur, ebselen, and tideglusib) and novel (CCG-50014, and CCG-203769) inhibitors using
fluorescence spectroscopy. We report both the catalytic efficiency of Mpro (Kcat / KM = 27,900 M1 -1

s M-1 s-1) and the IC50 values measured for tideglusib and ebselen (1.39 ± 0.2 µM and 0.40 ±

0.05 µM respectively) to be comparable to values published by Jin et al. [13]. We also report
that the novel CCG-50014 has comparable IC50 value (1.39 ± 0.22 µM) to known inhibitors of
this enzyme.
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Abbreviations: SARS, severe acute respiratory syndrome; MERS, Middle East respiratory
syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19,
coronavirus disease 2019; ACE2, angiotensin-converting enzyme 2; nonstructural protein, nsp;
ORF, open reading frame; main protease, MPro; thiadiazolidine, TDZD; regulators of G-protein
signaling, RGS; inhibitory concentration, IC50

Introduction
Coronaviruses are a large and diverse family of virus named for their unique crown-like
spike proteins that cover the virion surface. These viruses are infectious to humans and animals
and cause a variety of prevalent diseases with mild to severe symptoms. Coronavirus infections
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typically manifest as moderate upper-respiratory tract illnesses [1]. However, the past two
decades have seen coronavirus outbreaks with increasingly serious and fatal symptoms including
severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS)
in 2012, and most notably, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of coronavirus disease 2019 (COVID-19) [1, 2].
SARS-CoV-2 is a novel, β-coronavirus hypothesized to have zoonotic origins in bats [3]
as well as pangolins [4]. Symptoms range from mild; fever, cough, shortness of breath, to severe;
respiratory failure, pneumonia, and death. Outbreaks of the highly infectious COVID-19 virus
were first reported in December of 2019 in Wuhan, China. The virus spread rapidly and, in
March od 2020, a global pandemic was declared by the World Health Organization [3, 5]. The
ongoing pandemic has claimed the lives of almost 6.2 million people worldwide as of May 2022
[6] and has sparked an international research effort to understand the molecular mechanisms of
SARS-CoV-2 infection and develop effective treatments against its disease.
The virus is roughly 65-125 nm in diameter, and has a single stranded, positive sense,
RNA genome. The genome encodes four main structural proteins (S,E,M and N) essential to host
cell recognition and entry. The spike (S) protein is a transmembrane glycoprotein expressed on
the viral surface which interacts with host lower respiratory cell angiotensin-converting enzyme
2 (ACE2) receptors. The envelope (E) protein plays a role in viral maturation. The membrane
(M) protein determines viral envelope shape and assembly. The nucleocapsid (N) protein is an
RNA binding protein that is involved in viral transcription, translation, and replication. The
SARS-CoV-2 genome also encodes sixteen non-structural proteins (nsp 1-16) which have a
variety of functions including suppression of the host immune response, cleavage of
polyproteins, promotion of cytokine expression, and proofreading of the viral genome [3].
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Once the S protein attaches to host cell ACE2 receptors, the membranes fuse and viral
mRNA ready for translation enters the host cytoplasm. The genome contains fourteen open
reading frames (ORFs) that encode both the structural and non-structural proteins. Among the
first to be translated are the non-structural protein coding ORF1a and ORF1b which produce two
long, overlapping polyproteins pp1a and pp1b. pp1a and pp1b are made up of the sixteen
functional nsp polypeptides, including multiple proteins that aid in forming the polymerase and
helicase complexes essential to viral transcription and replication. Enzymatic digestion of pp1a
and pp1b is required to release the functional polypeptides from these larger polyproteins and
allow them to participate in the viral life cycle. The nsp5 enzyme, also known as the main
protease (MPro), is largely responsible for this digestion via its at least eleven conserved cut sites
along the length of pp1a and pp1b, including its own autolytic cleavage [3].
MPro is a roughly 34 kDa, homodimeric enzyme comprised of 306 amino acids per
monomer. Each monomer contains three subdomains, domains I and II (residues 8-101 and 102184, respectively) are characterized by mainly β-barrel motifs, while domain III (residues 201306) is primarily comprised of α-helices [7] (Fig. 1A). The MPro active site is situated at the
interface of domains I and II and is comprised of key active site residues; M49, G143, H163,
H164, E166, P168, Q189 and Y54, G143, H163 which form an oxyanion loop [8] (Fig. 1B). The
MPro active site cleaves peptide bonds using a catalytic dyad (Fig. 1B) in which the -SH group of
a cysteine residue (C145) donates a proton to the imidazole group of a histidine residue (H41)
[9]. This allows for cleavage at the following recognition site sequences: L-Q ↓ (S, A, G) [10,
11].
Because of its pivotal role in the viral life cycle, high sequence conservation with other
coronaviruses, and the lack of human homologues, MPro was identified as an attractive drug
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target for the treatment of COVID-19. Although vaccine development has tremendously reduced
the public health risks of COVID-19, the need for antiviral drugs to treat immunocompromised
and un-vaccinated patients is still pressing, especially in the face of rapidly emerging variants. In
December of 2021, the FDA announced its emergency authorization of Pfizer’s Paxlovid, an
MPro inhibitor and the first antiviral pill authorized to treat COVID-19 [12]. While the
development of Paxlovid again marks a major achievement in combating the global COVID-19
pandemic, more research into antiviral development is still necessary to increase drug efficacy
and reduce potential adverse side effects.
In this work we have investigated five potential small molecule MPro inhibitors, three of
which are known MPro inhibitors (carmofur, tideglusib, and ebselen), and two that are novel
(CCG-50014, and CCG-203769). The established inhibitors were pulled from a library of known
compounds with applications that were initially unrelated to SARS-CoV-2. They were then
repurposed and published in previous studies as effective MPro inhibitors [13, 14]. This study
tested the three known inhibitors with the intent of replicating the results previously reported by
Jin et al. [13] to optimize inhibition assay conditions and directly compare results with
structurally similar inhibitors. The two novel inhibitors were selected based on structural
similarity to tideglusib, a thiadiazolidine (TDZD) analog [15]. TDZD derivatives are known to
covalently modify the cysteine residues of the regulator of G-protein signaling (RGS) proteins
[16, 17, 18]. Because cysteine is an essential part of the MPro active site, it was hypothesized that
novel TDZD derived inhibitors would demonstrate comparable levels of MPro inhibition to
tideglusib. To investigate this hypothesis, recombinant MPro was expressed, and purified to test
the inhibitory effects of the five ligands using fluorescence spectroscopy. These studies were
used to complement molecular dynamics simulations for MPro inhibition [19].
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Figure 1: Structural details of Mpro monomer and active site. (A) Mpro monomer with domain I
(orange), domain II (purple), and domain III (blue). Key catalytic residues H41 (cyan) and C145
(yellow) also pictured. (B) A zoomed view of the active site with key residues colored, labeled
and shown in stick representations: M49 (red), G143 (pink), H163/H164 (gray), E166 (tan),
P168 (blue), Q189 (purple), and the backbone atoms of residues that form the oxyanion loop
(green). Figure was adapted from Padhi & Tripathi, 2021 [8].

Methods
MPro Expression and Purification
The expression vector, MPro-3C pET21b(+), containing the full-length SARS-CoV-2 gene
encoding MPro (NC_045512) was purchased from GenScript, with the gene sequence optimized
for expression in Escherichia coli. The final protein product contains four additional amino acids
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(GPGG) before the C-terminal 6xHis-tag. Protein expression and purification procedures
presented here were adopted and modified from Jin et. al [13]. The vector was transformed into
Escherichia coli Rosetta-gami B(DE3) cells (EMD Millipore), which were grown for 5-6 hours
in Luria-Bertani (LB) broth with 100 µg/mL ampicillin at 37 ˚C. Once the cells reached OD600
0.7, the over expression of MPro was induced by adding 0.5 mM IPTG to the medium. After 1112 hours of incubation at 16 ˚C, the liquid cell culture was centrifuged at 9,559 × g for 25
minutes (4 ˚C). The obtained Escherichia coli pellets were then stored -80 ˚C.
Protein purification started by thawing out a pellet at 4 ˚C for 30 minutes. Lysis buffer
containing 20 mM Tris-HCl (pH 7.3), 150 mM NaCl, HaltTM Protease Inhibitor cocktail (Thermo
Scientific) and Benzonase (EMD Millipore) were then added to the pellet. After 15-20 minutes
of incubation with Lysis buffer, the cells were fully re-suspended and subjected to four rounds of
mechanical cell lysis at 1,500 psi using the G-M French Press (Glen Mills). The cell lysate was
then centrifuged at 20,217 × g for 30 minutes (4 ˚C). The obtained supernatant was filtered
through 0.45- and 0.22-µm filters before purification. Since MPro was expressed with a Cterminal 6xHis-tag, the protein was purified using fast protein liquid chromatography system
(FPLC; GE Healthcare AKTA purifier 900) equipped with a HisTrap FF 1 mL column. The
protein was eluted from the column using an imidazole concentration gradient going up to 500
mM. The selected protein fractions were pooled, and imidazole was removed using ZebaTM spin
desalting columns (following manufacturer’s recommendation; Thermo Scientific). The sample
was brought up to 5 mL prior to subjecting it to another round of Ni-affinity chromatography
using a HisTrap HP 1 mL column. Upon collecting and pooling the selected fractions, the protein
sample was exchanged into buffer containing 50 mM Tris-HCl and 1 mM EDTA (pH = 7.3)
using ZebaTM spin desalting columns. The protein purity was assessed using SDS-PAGE. The
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protein concentration was measured using JASCO V-650 UV-vis spectrophotometer. Upon
determining the MPro purity and concentration, the protein identity was confirmed using LCMS/MS mass spectrometry.
Activity and Inhibition Assays
Since it was previously shown that C-terminal 6His-tag does not alter MPro activity, the
protease activity of uncleaved MPro containing the C-terminal 6His-tag was measured [20]. Both
the activity and inhibition assays were performed following a modified protocol originally
established by Jin et al. [13, 19] Fluorescence resonance energy transfer (FRET) peptide McaAVLQSGFRK(Dnp)K (GLBiochem) was used as the MPro substrate (excitation wavelength 325
nm, emission wavelength 392 nm). JASCO FP-8300 spectrofluorometer was used to measure the
MPro activity. 1 µM MPro (final concentration) was mixed with varying concentrations of the
peptide substrate (1.87 - 40 µM). Initial rates were obtained by fitting the linear portion of the
curves to a straight line (typically around 35 - 50 seconds) (Kinetic Analysis, JASCO). KM and
Vmax were calculated from the Lineweaver-Burk plot (1/V vs. 1/[S]) using Kinetic Analysis,
JASCO. These values were used to determine the Kcat (Vmax/[MPro]) as well as the catalytic
efficiency (Kcat/KM).
The degree of inhibition was measured for the three known MPro inhibitors [13, 14]
carmofur (Fig. 3), tideglusib (Fig. 4) and ebselen (Fig. 5); and two novel ones, CCG-2203769
(Fig. 6) and CCG-50014 (Fig. 7). The inhibition assays were performed on a microplate reader
SpectraMax Me (Molecular Devices). Similarly to the activity assays, fluorescence released the
Mca-AVLQSGFRK(Dnp)K peptide cleavage by MPro was measured. Each reaction contained 0.2
µM MPro, 20 µM FRET peptide, varied inhibitor concentration (0.025 - 100 µM), and 5% DMSO
in Assay buffer (50 mM Tris-HCl 1 mM EDTA pH 7.3). Data points were recorded every 4
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seconds for 5 minutes, at 30 ˚C. SoftMax Pro 7 (Molecular Devices) was used to calculate the
initial rates in units of relative fluorescence per second (RFU/s). The GraphPad Prism software
was used to calculate the IC50 values and plot the inhibition curves.

Results/Discussion
Activity Assay
The activity assay was performed before testing inhibition to verify that the catalytic
efficiency of MPro was comparable to the previously reported value by Jin et al. (Kcat / KM =
28,500 M-1 s-1) [13]. The Michaelis-Menten plot of [substrate] vs. RFU/min (Fig. 2) showed a
Michaelis constant (KM ) of 7.88 µM ± 2.62 μM and a maximum rate (Vmax) of 133.2 RFU/min.
These values were then used to calculate the turnover number (Kcat = 2.10 s-1 ± 0.61 s-1) and the
catalytic efficiency (Kcat / KM = 27,900 M-1 s-1 ± 6,250 M-1 s-1) which was comparable to the
value published by Jin et al. [13]. This confirmed that the IC50 values measured in the later
inhibition assays could be objectively compared to the previously reported values by Jin et al.
[13].
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Figure 2: Michaelis-Menten plot showing hyperbolic MPro saturation. Plot shows [substrate]
(uM) against reaction rate (RFU/min). Also shown is the KM value with the error and Vmax value.
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Inhibition Assays
The inhibition data was analyzed using plots of normalized inhibition versus log [I]. Each
inhibition plot exhibited a classic sigmoidal shape used to calculate the IC50 values. The IC50
values of the three known inhibitors, carmofur (Fig. 3), tideglusib (Fig. 4), and ebselen (Fig. 5)
were calculated first for comparison with the values of Jin et al. [13]. The IC50 values of
tideglusib (1.39 ± 0.2 µM) and ebselen (0.40 ± 0.05 µM) were comparable to reported values
[13], while the IC50 value for carmofur (4.45 ± 0.52 µM) was approximately 2.5-fold higher,
indicating that it may be a slightly weaker inhibitor of Mpro than previously reported. As our
measured IC50 values were comparable to those previously reported [13], it was assumed that the
inhibition assay could be used to reliably assess the potential of the two novel inhibitors and the
results could be objectively compared to the IC50 values published by Jin et al.

Figure 3: Normalized inhibition of MPro by carmofur (left) and carmofur chemical structure
(right). Plot shows the normalized inhibition percentage of MPro (y-axis) against the log of the
carmofur concentration (nM, x-axis). Also shown is the IC50 value with the error, and the
proportion of variance value
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Figure 4: Normalized inhibition of MPro by tideglusib (left) and tideglusib chemical structure
(right). Plot shows the normalized inhibition percentage of MPro (y-axis) against the log of the
tideglusib concentration (nM, x-axis). Also shown is the IC50 value with the error, and the
proportion of variance value.

Figure 5: Normalized inhibition of MPro by ebselen (left) and ebselen chemical structure (right).
Plot shows the normalized inhibition percentage of MPro (y-axis) against the log of the ebselen
concentration (nM, x-axis). Also shown is the IC50 value with the error, and the proportion of
variance value.
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The IC50 values of the two novel inhibitors; CCG-50014 and CCG-203769 were then
calculated using the same normalized inhibition vs log [I] plots. The IC50 value of CCG-50014
was 1.39 ± 0.22 µM (Fig. 6); thus CCG-50014 exhibited inhibition comparable to that tideglusib,
as hypothesized. These results are promising for CCG-50014’s potential application as an MPro
inhibitor. The IC50 value calculated for CCG-203769 was 10.95 ± 1.74 µM (Fig. 7). Because this
value was higher than CCG-50014 and all the known inhibitors, the compound showed less
potential as an MPro inhibitor.

Figure 6: Normalized inhibition of MPro by CCG-50014 (left) and CCG-50014 chemical
structure (right). Plot shows the normalized inhibition percentage of MPro (y-axis) against the log
of the CCG-50014 concentration (nM, x-axis). Also shown is the IC50 value with the error, and
the proportion of variance value.
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Figure 7: Normalized inhibition of MPro by CCG-203769 (left) and CCG-203769 chemical
structure (right). Plot shows the normalized inhibition percentage of MPro (y-axis) against the log
of the CCG-203769 concentration (nM, x-axis). Also shown is the IC50 value with the error, and
the proportion of variance value.
The difference in inhibition between CCG-50014 and CCG-203769 was attributed to the
different moieties attached to each structure’s thiazole ring. Where CCG-203769 has aliphatic
moieties attached to its central thiazole ring (an ethyl and a butyl group Fig. 7), CCG-50015 has
aromatic moieties attached (a methylbenzene and a fluorophenyl group Fig. 6). The molecular
dynamics studies (by the Vashisth group) complementary to this work showed these aromatic
moieties to be a stabilizing feature of CCG-50014’s interaction with the MPro active site. The
active site residues located closest to the fluorophenyl side chain were shown to be stabilized in
the presence of covalently-bound CCG-50014 through several stacking interactions and
hydrogen bonds. While the active site residues that showed increased fluctuations in the presence
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of CCG-5001 were those residues that did not have direct interactions with its aromatic sidechains [19].

Conclusions
In this work we have investigated inhibitory the potential of three known MPro inhibitors:
carmofur, tideglusib, and ebselen, and two novel MPro inhibitors: CCG-50014 and CCG-203769
using fluorescence spectroscopy assays. Both the catalytic efficiency of Mpro (Kcat / KM = 27,900
M-1 s-1 ± 6,250 M-1 s-1) and the IC50 values measured for tideglusib and ebselen (1.39 ± 0.2 µM
and 0.40 ± 0.05 µM respectively) are comparable to the values reported by Jin et al. [13]. The
IC50 value measured for carmofur (4.45 ± 0.52 µM) indicated it is a less potent MPro inhibitor
than previously reported [13]. The IC50 value measured for CCG-50014 (1.39 ± 0.22 µM) was
comparable to those of tideglusib, while the value for CCG-203769 (10.95 ± 1.74 µM) signified
it is a less potent inhibitor of MPro.
Molecular dynamics simulations revealed this difference to be because of the moieties
attached to each structure’s central thiazole ring. While CCG-50014 has aromatic moieties
attached, CCG-203769 has aliphatic moieties. The simulations showed these aromatic moieties
to have several stabilizing interactions with the key residues of the active site.
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